A Phase II Trial of Tarceva (Erlotinib) in Women With Squamous Cell Carcinoma of the Vulvar.
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2015
At a glance
- Drugs Erlotinib (Primary)
- Indications Vulvovaginal cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.